<span item_type="fundamental" item_id="00d244731de0c22af071b595216fda3e" counter_id="ST/US/LADX" env="prod"></span><span item_type="announcement" item_id="515950770668308993" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -1.45.</p><p></p><h3>Financial Metrics</h3><h4>Net Income (Loss)</h4><ul><li>The company reported a net loss of $719,291 for the three-month period ended March 31, 2025, compared to a net income of $186,735 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Research and development expenses were $28,808 for the three-month period ended March 31, 2025, compared to $30,296 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li><li>General and administrative expenses were $690,852 for the three-month period ended March 31, 2025, compared to $801,601 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities was $552,794 for the three months ended March 31, 2025, compared to $5,884 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul><h4>Stockholders’ Equity</h4><ul><li>Total stockholders’ equity (deficit) was -$2,134,792 as of March 31, 2025, compared to -$1,419,429 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>LadRx Corporation plans to submit aldoxorubicin to the US FDA for marketing approval approximately in the third quarter of 2026, following a small number of non-clinical studies, subject to agreement by the FDA.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The company is exploring the potential commercialization of aldoxorubicin itself or through licensing to a third party, with XOMA entitled to receive royalty payments and milestone payments under certain conditions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul><h4>Priority</h4><ul><li>The company expects the capital needed to reach the pre-NDA meeting to be approximately $1.5 million, and the capital needed to reach NDA marketing approval to be an additional $4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/799698/000164117225010063/form10-q.htm"></span></li></ul>

LadRx Corporation | 10-Q: FY2025 Q1 EPS: USD -1.45